Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8513817 | 1.00 | BACE1 (0.32) | BACE1CTSDNPSR1KDM4EMAPT | |
| SCHEMBL8513818 | 0.80 | BACE1 (0.33) | BACE1CTSDNPSR1KDM4EMAPT | |
| SCHEMBL8512252 | 0.79 | BACE1 (0.36) | BACE1CTSDNPSR1KDM4EMAPT | |
| SCHEMBL9611302 | 0.78 | BACE1 (0.35) | BACE1CTSDNPSR1KDM4EMAPT | |
| SCHEMBL2371832 | 0.78 | BACE1 (0.34) | BACE1CTSD | |
| SCHEMBL2370774 | 0.76 | AKR1B1 (0.35) | BACE1CTSD | |
| SCHEMBL8512549 | 0.75 | BACE1 (0.40) | BACE1CTSDNPSR1KDM4EMAPT | |
| SCHEMBL8513669 | 0.71 | AKR1B1 (0.35) | BACE1CTSD | |
| SCHEMBL15418574 | 0.70 | BACE1 (0.34) | BACE1CTSD | |
| SCHEMBL12213462 | 0.69 | BACE1 (0.30) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957083-B2 | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957083-B2 | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957083-B2 | Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130338177-A1 | Spiro-Amino-Imidazolone and Spiro-Amino-Dihydro-Pyrimidinone Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2643325-A1 | SPIRO-AMINO-IMIDAZOLONE AND SPIRO-AMINO-DIHYDRO-PYRIMIDINONE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012071279-A1 | SPIRO-AMINO-IMIDAZOLONE AND SPIRO-AMINO-DIHYDRO-PYRIMIDINONE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012071279-A1 | SPIRO-AMINO-IMIDAZOLONE AND SPIRO-AMINO-DIHYDRO-PYRIMIDINONE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338177-A1 | Spiro-Amino-Imidazolone and Spiro-Amino-Dihydro-Pyrimidinone Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | BACE1 1/4885CTSD 1045/4885NPSR1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.